EFFECT OF PRASUGREL VS CLOPIDOGREL ON HOSPITAL READMISSION AMONG ACUTE CORONARY SYNDROME PATIENTS TREATED WITH PRASUGREL
Author(s)
Olson WH1, Ma Y2, Lefebvre P3, Laliberté F3, Crivera C4, Schein JR4, Fields LE5, Dea K3, Germain G3, Lynch SM6
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Janssen Pharmaceuticals Inc., Titusville, NJ, USA, 3Groupe d’analyse, Ltée, Montréal, QC, Canada, 4Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 5Janssen Pharmaceuticals Inc., Raritan, NJ, USA, 6Department of Sociology, Princeton University, Princeton, NJ, USA
OBJECTIVES: During the last decade, the standard of care to treat acute coronary syndrome (ACS) patients was typically a combination of clopidogrel and aspirin. However, newer antiplatelet agents were approved recently. The aim of this study was to assess the effect on time-to-readmission and resource utilization of prasugrel vs. clopidogrel in prasugrel treated patients after hospitalization with an ACS event. METHODS: Based on the Truven Health Analytics MarketScan database from January 2009 through July 2012 a matched-cohort was created. Inferences for average treatment effect on time-to-readmission and numbers of hospitalizations, ER visits, and outpatient visits in prasugrel treated patients at 30 days and 1 year were performed by (1) frequentist Kaplan-Meier estimation with a log-rank test and Lin’s method for censored resource utilization outcomes; and (2) Bayesian discrete-time hazard models and negative binomial models. Bayes factors were also determined. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCV2
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Cardiovascular Disorders